Accordingly, anti-IL12/IL-23 (ustekinumab, which targets both Th1 and Th17(/Th1) responses) and anti-IL-23 (guselkumab, which targets Th17(/Th1) responses) may be attractive options for steroid-refractory ICI-pneumonitis, which have demonstrated clinical efficacy in systemic lupus erythematosus (SLE) and sjögren’s syndrome (SS) (Schinocca et al. 2021). This evidence concerns the gene IL23A and systemic lupus erythematosus.